Report Detail
Global Human Plasma-derived Hyperimmune Product Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4742386 |
- 28 September, 2026 |
- Global |
- 113 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Human Plasma-derived Hyperimmune Product market size was valued at US$ 2275 million in 2025 and is forecast to a readjusted size of US$ 3407 million by 2032 with a CAGR of 6.0% during review period.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
This report is a detailed and comprehensive analysis for global Human Plasma-derived Hyperimmune Product market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Plasma-derived Hyperimmune Product market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Human Plasma-derived Hyperimmune Product market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Human Plasma-derived Hyperimmune Product market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Human Plasma-derived Hyperimmune Product market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Plasma-derived Hyperimmune Product
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Plasma-derived Hyperimmune Product market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG, Hualan Bio, Shanghai RAAS, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Human Plasma-derived Hyperimmune Product market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Market segment by Application
Government Institution
Private Sector
Others
Major players covered
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Plasma-derived Hyperimmune Product product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Plasma-derived Hyperimmune Product, with price, sales quantity, revenue, and global market share of Human Plasma-derived Hyperimmune Product from 2021 to 2026.
Chapter 3, the Human Plasma-derived Hyperimmune Product competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Plasma-derived Hyperimmune Product breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Human Plasma-derived Hyperimmune Product market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Plasma-derived Hyperimmune Product.
Chapter 14 and 15, to describe Human Plasma-derived Hyperimmune Product sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Human Plasma-derived Hyperimmune Product Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Hepatitis B Immunoglobulins
- 1.3.3 Rabies Immunoglobulins
- 1.3.4 Tetanus Immunoglobulins
- 1.3.5 Rho(D) Immunoglobulins
- 1.3.6 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Human Plasma-derived Hyperimmune Product Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Government Institution
- 1.4.3 Private Sector
- 1.4.4 Others
- 1.5 Global Human Plasma-derived Hyperimmune Product Market Size & Forecast
- 1.5.1 Global Human Plasma-derived Hyperimmune Product Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Human Plasma-derived Hyperimmune Product Sales Quantity (2021-2032)
- 1.5.3 Global Human Plasma-derived Hyperimmune Product Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 CSL Behring
- 2.1.1 CSL Behring Details
- 2.1.2 CSL Behring Major Business
- 2.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Product and Services
- 2.1.4 CSL Behring Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 CSL Behring Recent Developments/Updates
- 2.2 Grifols
- 2.2.1 Grifols Details
- 2.2.2 Grifols Major Business
- 2.2.3 Grifols Human Plasma-derived Hyperimmune Product Product and Services
- 2.2.4 Grifols Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Grifols Recent Developments/Updates
- 2.3 Biotest
- 2.3.1 Biotest Details
- 2.3.2 Biotest Major Business
- 2.3.3 Biotest Human Plasma-derived Hyperimmune Product Product and Services
- 2.3.4 Biotest Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Biotest Recent Developments/Updates
- 2.4 Kedrion
- 2.4.1 Kedrion Details
- 2.4.2 Kedrion Major Business
- 2.4.3 Kedrion Human Plasma-derived Hyperimmune Product Product and Services
- 2.4.4 Kedrion Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Kedrion Recent Developments/Updates
- 2.5 CBPO
- 2.5.1 CBPO Details
- 2.5.2 CBPO Major Business
- 2.5.3 CBPO Human Plasma-derived Hyperimmune Product Product and Services
- 2.5.4 CBPO Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 CBPO Recent Developments/Updates
- 2.6 Emergent (Cangene)
- 2.6.1 Emergent (Cangene) Details
- 2.6.2 Emergent (Cangene) Major Business
- 2.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product and Services
- 2.6.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Emergent (Cangene) Recent Developments/Updates
- 2.7 Kamada
- 2.7.1 Kamada Details
- 2.7.2 Kamada Major Business
- 2.7.3 Kamada Human Plasma-derived Hyperimmune Product Product and Services
- 2.7.4 Kamada Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Kamada Recent Developments/Updates
- 2.8 CNBG
- 2.8.1 CNBG Details
- 2.8.2 CNBG Major Business
- 2.8.3 CNBG Human Plasma-derived Hyperimmune Product Product and Services
- 2.8.4 CNBG Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 CNBG Recent Developments/Updates
- 2.9 Hualan Bio
- 2.9.1 Hualan Bio Details
- 2.9.2 Hualan Bio Major Business
- 2.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Product and Services
- 2.9.4 Hualan Bio Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Hualan Bio Recent Developments/Updates
- 2.10 Shanghai RAAS
- 2.10.1 Shanghai RAAS Details
- 2.10.2 Shanghai RAAS Major Business
- 2.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product and Services
- 2.10.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Shanghai RAAS Recent Developments/Updates
- 2.11 Sichuan Yuanda Shuyang
- 2.11.1 Sichuan Yuanda Shuyang Details
- 2.11.2 Sichuan Yuanda Shuyang Major Business
- 2.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product and Services
- 2.11.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
- 2.12 ADMA Biologics
- 2.12.1 ADMA Biologics Details
- 2.12.2 ADMA Biologics Major Business
- 2.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Product and Services
- 2.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 ADMA Biologics Recent Developments/Updates
3 Competitive Environment: Human Plasma-derived Hyperimmune Product by Manufacturer
- 3.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturer (2021-2026)
- 3.3 Global Human Plasma-derived Hyperimmune Product Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Human Plasma-derived Hyperimmune Product by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Human Plasma-derived Hyperimmune Product Manufacturer Market Share in 2025
- 3.4.3 Top 6 Human Plasma-derived Hyperimmune Product Manufacturer Market Share in 2025
- 3.5 Human Plasma-derived Hyperimmune Product Market: Overall Company Footprint Analysis
- 3.5.1 Human Plasma-derived Hyperimmune Product Market: Region Footprint
- 3.5.2 Human Plasma-derived Hyperimmune Product Market: Company Product Type Footprint
- 3.5.3 Human Plasma-derived Hyperimmune Product Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Human Plasma-derived Hyperimmune Product Market Size by Region
- 4.1.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2021-2032)
- 4.1.2 Global Human Plasma-derived Hyperimmune Product Consumption Value by Region (2021-2032)
- 4.1.3 Global Human Plasma-derived Hyperimmune Product Average Price by Region (2021-2032)
- 4.2 North America Human Plasma-derived Hyperimmune Product Consumption Value (2021-2032)
- 4.3 Europe Human Plasma-derived Hyperimmune Product Consumption Value (2021-2032)
- 4.4 Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value (2021-2032)
- 4.5 South America Human Plasma-derived Hyperimmune Product Consumption Value (2021-2032)
- 4.6 Middle East & Africa Human Plasma-derived Hyperimmune Product Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2021-2032)
- 5.2 Global Human Plasma-derived Hyperimmune Product Consumption Value by Type (2021-2032)
- 5.3 Global Human Plasma-derived Hyperimmune Product Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2021-2032)
- 6.2 Global Human Plasma-derived Hyperimmune Product Consumption Value by Application (2021-2032)
- 6.3 Global Human Plasma-derived Hyperimmune Product Average Price by Application (2021-2032)
7 North America
- 7.1 North America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2021-2032)
- 7.2 North America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2021-2032)
- 7.3 North America Human Plasma-derived Hyperimmune Product Market Size by Country
- 7.3.1 North America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2021-2032)
- 7.3.2 North America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2021-2032)
- 8.2 Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2021-2032)
- 8.3 Europe Human Plasma-derived Hyperimmune Product Market Size by Country
- 8.3.1 Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Human Plasma-derived Hyperimmune Product Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Human Plasma-derived Hyperimmune Product Market Size by Region
- 9.3.1 Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2021-2032)
- 10.2 South America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2021-2032)
- 10.3 South America Human Plasma-derived Hyperimmune Product Market Size by Country
- 10.3.1 South America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2021-2032)
- 10.3.2 South America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Human Plasma-derived Hyperimmune Product Market Size by Country
- 11.3.1 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Human Plasma-derived Hyperimmune Product Market Drivers
- 12.2 Human Plasma-derived Hyperimmune Product Market Restraints
- 12.3 Human Plasma-derived Hyperimmune Product Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Human Plasma-derived Hyperimmune Product and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Human Plasma-derived Hyperimmune Product
- 13.3 Human Plasma-derived Hyperimmune Product Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Human Plasma-derived Hyperimmune Product Typical Distributors
- 14.3 Human Plasma-derived Hyperimmune Product Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Human Plasma-derived Hyperimmune Product. Industry analysis & Market Report on Human Plasma-derived Hyperimmune Product is a syndicated market report, published as Global Human Plasma-derived Hyperimmune Product Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Human Plasma-derived Hyperimmune Product market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
